Absence of Association between Cord Specific Antibody Levels and Severe Respiratory Syncytial Virus (RSV) Disease in Early Infants: A Case Control Study from Coastal Kenya
- PMID: 27851799
- PMCID: PMC5113039
- DOI: 10.1371/journal.pone.0166706
Absence of Association between Cord Specific Antibody Levels and Severe Respiratory Syncytial Virus (RSV) Disease in Early Infants: A Case Control Study from Coastal Kenya
Abstract
Background: The target group for severe respiratory syncytial virus (RSV) disease prevention is infants under 6 months of age. Vaccine boosting of antibody titres in pregnant mothers could protect these young infants from severe respiratory syncytial virus (RSV) associated disease. Quantifying protective levels of RSV-specific maternal antibody at birth would inform vaccine development.
Methods: A case control study nested in a birth cohort (2002-07) was conducted in Kilifi, Kenya; where 30 hospitalised cases of RSV-associated severe disease were matched to 60 controls. Participants had a cord blood and 2 subsequent 3-monthly blood samples assayed for RSV-specific neutralising antibody by the plaque reduction neutralisation test (PRNT). Two sample paired t test and conditional logistic regression were used in analyses of log2PRNT titres.
Results: The mean RSV log2PRNT titre at birth for cases and controls were not significantly different (P = 0.4) and remained so on age-stratification. Cord blood PRNT titres showed considerable overlap between cases and controls. The odds of RSV disease decreased with increase in log2PRNT cord blood titre. There was a 30% reduction in RSV disease per unit increase in log2PRNT titre (<3months age group) but not significant (P = 0.3).
Conclusions: From this study, there is no strong evidence of protection by maternal RSV specific antibodies from severe RSV disease. Cord antibody levels show wide variation with considerable overlap between cases and controls. It is likely that, there are additional factors to specific PRNT antibody levels which determine susceptibility to severe RSV disease. In addition, higher levels of neutralizing antibody beyond the normal range may be required for protection; which it is hoped can be achieved by a maternal RSV vaccine.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
![Fig 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5113039/bin/pone.0166706.g001.gif)
![Fig 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5113039/bin/pone.0166706.g002.gif)
![Fig 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5113039/bin/pone.0166706.g003.gif)
![Fig 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5113039/bin/pone.0166706.g004.gif)
![Fig 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5113039/bin/pone.0166706.g005.gif)
Similar articles
-
Quantifying maternally derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal Kenya.Vaccine. 2015 Apr 8;33(15):1797-801. doi: 10.1016/j.vaccine.2015.02.039. Epub 2015 Feb 26. Vaccine. 2015. PMID: 25725445 Free PMC article.
-
Transplacental transfer of maternal respiratory syncytial virus (RSV) antibody and protection against RSV disease in infants in rural Nepal.J Clin Virol. 2017 Oct;95:90-95. doi: 10.1016/j.jcv.2017.08.017. Epub 2017 Sep 2. J Clin Virol. 2017. PMID: 28903080 Free PMC article.
-
Kinetics of the neutralizing antibody response to respiratory syncytial virus infections in a birth cohort.J Med Virol. 2013 Nov;85(11):2020-5. doi: 10.1002/jmv.23696. J Med Virol. 2013. PMID: 23983183 Free PMC article.
-
Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?Curr Opin Infect Dis. 2015 Jun;28(3):221-4. doi: 10.1097/QCO.0000000000000161. Curr Opin Infect Dis. 2015. PMID: 25918956 Review.
-
Passive protection against respiratory syncytial virus disease in infants: the role of maternal antibody.Pediatr Infect Dis J. 1994 May;13(5):449-53. doi: 10.1097/00006454-199405000-00037. Pediatr Infect Dis J. 1994. PMID: 8072835 Review.
Cited by
-
Difference in respiratory syncytial virus-specific Fc-mediated antibody effector functions between children and adults.Clin Exp Immunol. 2023 Dec 11;214(1):79-93. doi: 10.1093/cei/uxad101. Clin Exp Immunol. 2023. PMID: 37605554 Free PMC article. Review.
-
Correlates of Protection Against Respiratory Syncytial Virus Infection in Infancy.Clin Rev Allergy Immunol. 2022 Dec;63(3):371-380. doi: 10.1007/s12016-022-08948-8. Epub 2022 Jun 11. Clin Rev Allergy Immunol. 2022. PMID: 35689745 Review.
-
Bronchiolitis hospitalizations in rural New England: clues to disease prevention.Ther Adv Infect Dis. 2022 May 27;9:20499361221099447. doi: 10.1177/20499361221099447. eCollection 2022 Jan-Dec. Ther Adv Infect Dis. 2022. PMID: 35651526 Free PMC article.
-
Respiratory Syncytial Virus (RSV)-Specific Antibodies in Pregnant Women and Subsequent Risk of RSV Hospitalization in Young Infants.J Infect Dis. 2022 Apr 1;225(7):1189-1196. doi: 10.1093/infdis/jiab315. J Infect Dis. 2022. PMID: 34129040 Free PMC article.
-
Global Perspectives on Immunization During Pregnancy and Priorities for Future Research and Development: An International Consensus Statement.Front Immunol. 2020 Jun 24;11:1282. doi: 10.3389/fimmu.2020.01282. eCollection 2020. Front Immunol. 2020. PMID: 32670282 Free PMC article. Review.
References
-
- Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89(4):422–34. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical